Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens.

Mattsson J, Ljungars A, Carlsson A, Svensson C, Nilsson B, Ohlin M, Frendéus B

Cell Reports Methods 3 (5) 100475 [2023-05-22; online 2023-05-09]

Phenotypic drug discovery (PDD) enables the target-agnostic generation of therapeutic drugs with novel mechanisms of action. However, realizing its full potential for biologics discovery requires new technologies to produce antibodies to all, a priori unknown, disease-associated biomolecules. We present a methodology that helps achieve this by integrating computational modeling, differential antibody display selection, and massive parallel sequencing. The method uses the law of mass action-based computational modeling to optimize antibody display selection and, by matching computationally modeled and experimentally selected sequence enrichment profiles, predict which antibody sequences encode specificity for disease-associated biomolecules. Applied to a phage display antibody library and cell-based antibody selection, ∼105 antibody sequences encoding specificity for tumor cell surface receptors expressed at 103-106 receptors/cell were discovered. We anticipate that this approach will be broadly applicable to molecular libraries coupling genotype to phenotype and to the screening of complex antigen populations for identification of antibodies to unknown disease-associated targets.

Drug Discovery and Development (DDD) [Service]

PubMed 37323567

DOI 10.1016/j.crmeth.2023.100475

Crossref 10.1016/j.crmeth.2023.100475

pmc: PMC10261905
pii: S2667-2375(23)00098-X

Publications 9.5.0